Author:
Dudzisz-Śledź Monika,Zwierzchowska Martyna,Bylina Elżbieta,Rutkowski Piotr,Czarnecka Anna M.
Publisher
Springer International Publishing
Reference37 articles.
1. Ascierto PA, Orlova K, Grignani G, Dudzisz-Sledz M, Fenig E, Chiarion Sileni V et al (2021) Avelumab expanded access program in metastatic Merkel cell carcinoma: efficacy and safety findings from patients in Europe and the Middle East. Int J Cancer 149(11):1926–1934
2. Bhanegaonkar A, Liu FX, Kim R, Boyd M, Fulcher N, Krulewicz S et al (2020) Real-world clinical outcomes in avelumab-treated patients (pts) in the United States (U.S.) from SPEAR-Merkel: study informing treatment pathway decisions in Merkel cell carcinoma (MCC). J Clin Oncol 38(29_suppl):269
3. Bharmal M, Nolte S, Lebbe C, Mortier L, Brohl AS, Fazio N et al (2020) Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. Future Oncol 16(27):2089–2099
4. Bhatia S, Brohl AS, Brownell I, Chandra S, Dakhil S, Ernstoff MS et al (2018) ADAM trial: a multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases. NCT03271372 36(15_suppl):TPS9605-TPS
5. Bullement A, D’Angelo SP, Amin A, Stapelkamp C, Willis A, Lilley C et al (2018) Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab. J Clin Oncol 36(15_suppl):e21620-e